Serum sphingolipid profiling as a novel biomarker for metabolic syndrome characterization
BackgroundSphingolipids are components of cell membrane structure, but also circulate in serum and are essential mediators of many cellular functions. While ceramides have been proposed previously as a useful biomarker for cardiometabolic disease, the involvement of other sphingolipids is still cont...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-12-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2022.1092331/full |
| _version_ | 1811202406941196288 |
|---|---|
| author | Loni Berkowitz Cristian Salazar Carol D. Ryff Christopher L. Coe Attilio Rigotti |
| author_facet | Loni Berkowitz Cristian Salazar Carol D. Ryff Christopher L. Coe Attilio Rigotti |
| author_sort | Loni Berkowitz |
| collection | DOAJ |
| description | BackgroundSphingolipids are components of cell membrane structure, but also circulate in serum and are essential mediators of many cellular functions. While ceramides have been proposed previously as a useful biomarker for cardiometabolic disease, the involvement of other sphingolipids is still controversial. The aim of this study was to investigate the cross-sectional association between blood sphingolipidomic profiles and metabolic syndrome (MetS) as well as other atherosclerotic risk factors in a large population-based study in the U.S.MethodsClinical data and serum sphingolipidomic profiling from 2,063 subjects who participated in the biomarker project of the Midlife in the United States (MIDUS) study were used.ResultsConsistent with previous reports, we found a positive association between most ceramide levels and obesity, atherogenic dyslipidemia, impaired glucose metabolism, and MetS prevalence. In contrast, most simple β-glycosphingolipids (i.e., hexosylceramides and lactosylceramides) were inversely associated with dysmetabolic biomarkers. However, this latter sphingolipid class showed a positive link with inflammatory and vascular damage-associated biomarkers in subjects with MetS. Through metabolic network analysis, we found that the relationship between ceramides and simple β-glycosphingolipids differed significantly not only according to MetS status, but also with respect to the participants' C-reactive protein levels.ConclusionOur findings suggest that a comprehensive sphingolipid profile is more informative about MetS than ceramides alone, and it may reveal new insights into the pathophysiology and further diabetic vs. cardiovascular risk in patients with MetS. |
| first_indexed | 2024-04-12T02:39:01Z |
| format | Article |
| id | doaj.art-9e98e41c0fcc4b4a86e80ebe981ef313 |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-04-12T02:39:01Z |
| publishDate | 2022-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-9e98e41c0fcc4b4a86e80ebe981ef3132022-12-22T03:51:24ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2022-12-01910.3389/fcvm.2022.10923311092331Serum sphingolipid profiling as a novel biomarker for metabolic syndrome characterizationLoni Berkowitz0Cristian Salazar1Carol D. Ryff2Christopher L. Coe3Attilio Rigotti4Center of Molecular Nutrition and Chronic Diseases, Department of Nutrition, Diabetes and Metabolism, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, ChileCenter of Molecular Nutrition and Chronic Diseases, Department of Nutrition, Diabetes and Metabolism, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, ChileInstitute on Aging, University of Wisconsin-Madison, Madison, WI, United StatesInstitute on Aging, University of Wisconsin-Madison, Madison, WI, United StatesCenter of Molecular Nutrition and Chronic Diseases, Department of Nutrition, Diabetes and Metabolism, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, ChileBackgroundSphingolipids are components of cell membrane structure, but also circulate in serum and are essential mediators of many cellular functions. While ceramides have been proposed previously as a useful biomarker for cardiometabolic disease, the involvement of other sphingolipids is still controversial. The aim of this study was to investigate the cross-sectional association between blood sphingolipidomic profiles and metabolic syndrome (MetS) as well as other atherosclerotic risk factors in a large population-based study in the U.S.MethodsClinical data and serum sphingolipidomic profiling from 2,063 subjects who participated in the biomarker project of the Midlife in the United States (MIDUS) study were used.ResultsConsistent with previous reports, we found a positive association between most ceramide levels and obesity, atherogenic dyslipidemia, impaired glucose metabolism, and MetS prevalence. In contrast, most simple β-glycosphingolipids (i.e., hexosylceramides and lactosylceramides) were inversely associated with dysmetabolic biomarkers. However, this latter sphingolipid class showed a positive link with inflammatory and vascular damage-associated biomarkers in subjects with MetS. Through metabolic network analysis, we found that the relationship between ceramides and simple β-glycosphingolipids differed significantly not only according to MetS status, but also with respect to the participants' C-reactive protein levels.ConclusionOur findings suggest that a comprehensive sphingolipid profile is more informative about MetS than ceramides alone, and it may reveal new insights into the pathophysiology and further diabetic vs. cardiovascular risk in patients with MetS.https://www.frontiersin.org/articles/10.3389/fcvm.2022.1092331/fullsphingolipidsceramidesmetabolic syndromeinflammationcardiovascular risklactosylceramide |
| spellingShingle | Loni Berkowitz Cristian Salazar Carol D. Ryff Christopher L. Coe Attilio Rigotti Serum sphingolipid profiling as a novel biomarker for metabolic syndrome characterization Frontiers in Cardiovascular Medicine sphingolipids ceramides metabolic syndrome inflammation cardiovascular risk lactosylceramide |
| title | Serum sphingolipid profiling as a novel biomarker for metabolic syndrome characterization |
| title_full | Serum sphingolipid profiling as a novel biomarker for metabolic syndrome characterization |
| title_fullStr | Serum sphingolipid profiling as a novel biomarker for metabolic syndrome characterization |
| title_full_unstemmed | Serum sphingolipid profiling as a novel biomarker for metabolic syndrome characterization |
| title_short | Serum sphingolipid profiling as a novel biomarker for metabolic syndrome characterization |
| title_sort | serum sphingolipid profiling as a novel biomarker for metabolic syndrome characterization |
| topic | sphingolipids ceramides metabolic syndrome inflammation cardiovascular risk lactosylceramide |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2022.1092331/full |
| work_keys_str_mv | AT loniberkowitz serumsphingolipidprofilingasanovelbiomarkerformetabolicsyndromecharacterization AT cristiansalazar serumsphingolipidprofilingasanovelbiomarkerformetabolicsyndromecharacterization AT caroldryff serumsphingolipidprofilingasanovelbiomarkerformetabolicsyndromecharacterization AT christopherlcoe serumsphingolipidprofilingasanovelbiomarkerformetabolicsyndromecharacterization AT attiliorigotti serumsphingolipidprofilingasanovelbiomarkerformetabolicsyndromecharacterization |